A password will be e-mailed to you.

Last UpdatedMarch 19, 201812:02 AM EDT TORONTO — Sandoz Canada Inc. is partnering with B.C. cannabis company Tilray to develop and distribute medical marijuana products, signalling the first deal between a major pharmaceutical company and a Canadian cannabis producer. The companies announced Sunday that they’ve signed a binding letter of intent to form a “strategic partnership.” This will see co-branded products, joint research and development, and Sandoz Canada’s sales team helping to get non-smokable Tilray products into pharmacies and hospitals across the country, pending regulatory approval. Sandoz Canada is a branch of Sandoz International GmbH, the generics-focused wing of Novartis International AG, the fourth-largest pharmaceutical company in the world by revenue. Nanaimo, B.C.-based Tilray, a private company owned by Seattle cannabis investment firm Privateer Holdings, has considerable experience in the regulated cannabis space. Big Pharma’s first foray into cannabis arrives with Sandoz-Tilray deal

thumbnail courtesy of financialpost.com


No more articles